Liver Assist Device

[Guest guest]

A company

developing proprietary medical devices and cell-based therapies for the

millions of patients each year who experience or are at risk for

life-threatening episodes of liver failure, today announced further favorable,

preliminary results following the enrollment of 15 patients in the feasibility

clinical trial of its SEPET Liver Assist Device.

Continued

high, rapid rates of disease response have been observed in the SEPET

treatments thus far, involving reversal of hepatic encephalopathy (also known

as liver coma) associated with acute episodes of liver failure in patients with

chronic liver disease and advanced cirrhosis.

The

SEPET feasibility study has so far enrolled patients suffering hepatic

encephalopathy ranging from Grade 2 (characterized by pronounced lethargy and

loss of muscle motor control) to Grade 3 (inability to remain awake) to Grade 4

(coma). The majority of patients in the study have had

Grade 3 encephalopathy at the outset of treatment, and patients have been

provided up to four, sequential, daily SEPET treatments, generally until

they achieved a durable, stable disease response. Preliminary

analysis of the clinical trial results indicates an approximate 70% overall

response rate (reduction of encephalopathy by at least two grades) with another

approximately 20% of patients achieving a partial response (reduction of

encephalopathy by one grade).

The

SEPET Liver Assist Device is a sterile, disposable cartridge containing microporous hollow fibers with unique permeability

characteristics. When a patient's blood is passed

through these fibers, blood plasma components of specific molecular weights are

expressed through the micropores, thereby cleansing

the blood of harmful impurities……….

http://www.pr-inside.com/rss/arbios-systems-reports-favorable-results-from-the-sepettm-feasibility-clinical-trial-r84134.htm

Barb in Texas - Together in the Fight, Whatever it Takes!

Son Ken (32) UC 91 - PSC 99 Listed 7/21 @ Baylor Dallas